Interleukin 10: A new risk marker for the development of restenosis after percutaneous coronary intervention

Genes and Immunity

Volumn 8, Issue 1, 2007, Pages 44-50

  Monraats, P S ^a,b   Kurreeman, F A S ^a   Pons, D ^a   Sewgobind, V D K D ^a   de Vries, F R ^a   Zwinderman, A H ^c   de Maat, M P M ^d   Doevendans, P A ^e   de Winter, R J ^c   Tio, R A ^f   Waltenberger, J ^g   Huizinga, T W J ^a   Eefting, D ^a,h   Quax, P H A ^a,h   Frants, R R ^a   van der Laarse, A ^a   van der Wall, E E ^a   Jukema, J W ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^h TNO   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CLOPIDOGREL; CYSTEINE; GLYCINE; INTERLEUKIN 10; TICLOPIDINE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DISEASE MARKER; DNA FLANKING REGION; DNA MICROARRAY; DRUG ELUTING STENT; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; HYPOTHESIS; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK FACTOR;

3' UNTRANSLATED REGIONS; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY RESTENOSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFLAMMATION; INTERLEUKIN-10; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 33846548581     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/sj.gene.6364343     Document Type: Article

References (28)

1. Mehilli J, Kastrati A, Bollwein H, Dibra A, Schuhlen H, Dirschinger J et al. Gender and restenosis after coronary artery stenting. Eur Heart J 2003; 24: 1523-1530.
2. Schomig A, Kastrati A, Elezi S, Schuhlen H, Dirschinger J, Dannegger F et al. Bimodal distribution of angiographic measures of restenosis six months after coronary stent placement. Circulation 1997; 96: 3880-3887.
3. Sharif F, Daly K, Crowley J, O'Brien T. Current status of catheter- and stent-based gene therapy. Cardiovasc Res 2004; 64: 208-216.
4. Agema WR, Jukema JW, Pimstone SN, Kastelein JJ. Genetic aspects of restenosis after percutaneous coronary interventions: Towards more tailored therapy. Eur Heart J 2001; 22: 2058-2074.
5. Monraats PS, Pires NM, Agema WR, Zwinderman AH, Schepers A, De Maat MP et al. Genetic inflammatory factors predict restenosis after percutaneous coronary interventions. Circulation 2005; 112: 2417-2425.
6. De Maat MP, Jukema JW, Ye S, Zwinderman AH, Moghaddam PH, Beekman M et al. Effect of the stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restenosis. Am J Cardiol 1999; 83: 852-856.
7. Kastrati A, Koch W, Berger PB, Mehilli J, Stephenson K, Neumann FJ et al. Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. J Am Coll Cardiol 2000; 36: 2168-2173.
8. Lowe PR, Galley HF, Abdel-Fattah A, Webster NR. Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients. Crit Care Med 2003; 31: 34-38.
9. Mazighi M, Pelle A, Gonzalez W, Mtairag EM, Philippe M, Henin D et al. IL-10 inhibits vascular smooth muscle cell activation in vitro and in vivo. Am J Physiol Heart Circ Physiol 2004; 287: H866-H871.
10. Suarez A, Castro P, Alonso R, Mozo L, Gutierrez C. Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation 2003; 75: 711-717.
11. Monraats PS, Pires NM, Schepers A, Agema WR, Boesten LS, de Vries MR et al. Tumor necrosis factor-alpha plays an important role in restenosis development. FASEB J 2005; 19: 1998-2004.
12. de Jong BA, Westendorp RG, Eskdale J, Uitdehaag BM, Huizinga TW. Frequency of functional interleukin-10 promoter polymorphism is different between relapse-onset and primary progressive multiple sclerosis. Hum Immunol 2002; 63: 281-285.
13. Koss K, Satsangi J, Fanning GC, Welsh KI, Jewell DP. Cytokine (TNF alpha, LT alpha and IL-10) polymorphisms in inflammatory bowel diseases and normal controls: Differential effects on production and allele frequencies. Genes Immun 2000; 1: 185-190.
14. Kurreeman FA, Schonkeren JJ, Heijmans BT, Toes RE, Huizinga TW. Transcription of the IL10 gene reveals allele-specific regulation at the mRNA level. Hum Mol Genet 2004; 13: 1755-1762.
15. Westendorp RG, Langermans JA, Huizinga TW, Verweij CL, Sturk A. Genetic influence on cytokine production in meningococcal disease. Lancet 1997; 349: 1912-1913.
16. Cassatella MA, Meda L, Bonora S, Ceska M, Constantin G. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med 1993; 178: 2207-2211.
17. Kasama T, Strieter RM, Lukacs NW, Burdick MD, Kunkel SL. Regulation of neutrophil-derived chemokine expression by IL-10. J Immunol 1994; 152: 3559-3569.
18. Krakauer T. IL-10 inhibits the adhesion of leukocytic cells to IL-1-activated human endothelial cells. Immunol Lett 1995; 45: 61-65.
19. Cassatella MA, Meda L, Gasperini S, Calzetti F, Bonora S. Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. J Exp Med 1994; 179: 1695-1699.
20. Booy R, Nadel S, Hibberd M, Levin M, Newport MJ. Genetic influence on cytokine production in meningococcal disease. Lancet 1997; 349: 1176.
21. Westendorp RG, van Dunne FM, Kirkwood TB, Helmerhorst FM, Huizinga TW. Optimizing human fertility and survival. Nat Med 2001; 7: 873.
22. Liu YW, Chen CC, Tseng HP, Chang WC. Lipopolysaccharide-induced transcriptional activation of interleukin-10 is mediated by MAPK- and NF-kappaB-induced CCAAT/enhancer-binding protein delta in mouse macrophages. Cell Signal 2006; 18: 1492-1500.
23. Riemann M, Endres R, Liptay S, Pfeffer K, Schmid RM. The IkappaB protein Bcl-3 negatively regulates transcription of the IL-10 gene in macrophages. J Immunol 2005; 175: 3560-3568.
24. Eefting D, Schepers A, de Vries MR, Pires NMM, Grimbergen JM, Lagerweij T et al. The effect of interleukin-10 knock-out and overexpression on neointima formation in hypercholesterolemic ApoE3Leiden mice. Manuscript in progress.
25. Feldman LJ, Aguirre L, Ziol M, Bridou JP, Nevo N, Michel JB et al. Interleukin-10 inhibits intimal hyperplasia after angioplasty or stent implantation in hypercholesterolemic rabbits. Circulation 2000; 101: 908-916.
26. Agema WRP, Monraats PS, Zwinderman AH, de Winter RJ, Tio RA, Doevendans PAFM et al. Current PTCA practice and clinical outcomes in The Netherlands: The real world in the pre-drug-eluting stent era. Eur Heart J 2004; 25: 1163-1170.
27. Li W, Nyholt DR. Marker selection by Akaike information criterion and Bayesian information criterion. Genet Epidemiol 2001; 21 (Suppl 1): S272-S277.
28. Tanck MW, Klerkx AH, Jukema JW, De Knijff P, Kastelein JJ, Zwinderman AH. Estimation of multilocus haplotype effects using weighted penalised log-likelihood: Analysis of five sequence variations at the cholesteryl ester transfer protein gene locus. Ann Hum Genet 2003; 67: 175-184.